Results 141 to 150 of about 156,017 (326)

Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)

, 2022
Joshua Tobin, Shivang Joshi, Janet H. Ford, Russell Nichols, Shonda A. Foster, Dustin Ruff, Holland C. Detke, Sheena K. Aurora   +7 more
openalex   +1 more source

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches.
Keiichi Akahoshi, Shun Kaneko, Shinji Tanaka, Minoru Tanabe, Daisuke Ban   +4 more
wiley   +1 more source

The therapeutic oxymoron: exploring the mechanisms of open-label placebo

, 2023
Placebos have emancipated themselves from earlier, often unethical or merely research- based practices, toward an open and thereby ethical administration. Despite a plethora of efficacy studies and nearly two decades of empirical research on open-label placebos (OLPs), little to nothing is known about the circumstances under which they realize their ...
openaire   +2 more sources

Predicting Postresection Colorectal Liver Metastases Recurrence Using Advanced Graph Neural Networks with Explainability and Causal Inference

Advanced Intelligent Systems, EarlyView.
This study introduces a framework that combines graph neural networks with causal inference to forecast recurrence and uncover the clinical and pathological factors driving it. It further provides interpretability, validates risk factors via counterfactual and interventional analyses, and offers evidence‐based insights for treatment planning ...
Jubair Ahmed, Md. Abdur Rahman, Mohaimenul Azam Khan Raiaan, Sami Azam   +3 more
wiley   +1 more source

Open label placebo: pill and needle

Integrative Medicine Research, 2020
Dha-Hyun Choi, In-Seon Lee, Younbyoung Chae   +2 more
openaire   +2 more sources

Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension [PDF]

, 2011
Veronika Vakhapova, Yael Richter, Tzafra Cohen, Yael Herzog, Amos D. Korczyn   +4 more
openalex   +1 more source

No long-term effects after a 3-week open-label placebo treatment for chronic low back pain: a 3-year follow-up of a randomized controlled trial

, 2022
Julian Kleine‐Borgmann, Tim-Niklas Dietz, Katharina Schmidt, Ulrike Bingel   +3 more
openalex   +1 more source

Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial [PDF]

, 2014
Background: This study aimed to assess the efficacy of topiramate, a glutamate-modulating agent, in patients with treatment-resistant obsessive-compulsive disorder (OCD) as an adjunct to serotonin reuptake inhibitors (SRIs).
Afshar, Hamid., Akuchekian, Shahla., Mahaki, Behzad., Zarean, Elham.   +3 more
core   +2 more sources

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

American Journal of Hematology, EarlyView.
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs, Elizabeth A. Abels, Brian D. Adkins, Garrett S. Booth, Victoria Costa, Sheharyar Raza, Michelle Simon, Jennifer S. Woo, Allison P. Wheeler   +8 more
wiley   +1 more source

Would You Take an Open-Label Placebo Pill or Give One to Your Child? Findings from a Cross-Sectional Survey

Psychology Research and Behavior Management
Anne Schienle, Arved Seibel Department of Clinical Psychology, University of Graz, Graz, AustriaCorrespondence: Anne Schienle, Email anne.schienle@uni-graz.atBackground: Open-label placebos (OLPs), honestly prescribed regarding their inert nature, have ...
Schienle A, Seibel A
doaj